Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Allergence
About Us
SnackSafely.com Media Kit
SnackSafely.com Advertising Guide
Subscribe to our newsletter
Contact Us
Resources
FAQ
Partner Manufacturers
Tools for Schools
Coupons
Inspiring Food Allergy Bloggers and Authors
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Home
Safe Snack Guide
Peanut and Tree Nut Free Edition
Milk Free Edition
Sesame Free Edition
Gluten Free Edition
Allergence
About Us
SnackSafely.com Media Kit
SnackSafely.com Advertising Guide
Subscribe to our newsletter
Contact Us
Resources
FAQ
Partner Manufacturers
Tools for Schools
Coupons
Inspiring Food Allergy Bloggers and Authors
Search
Tag: Sanofi
FDA Approves Dupixent® as First Biologic for Treatment of Children Aged...
News Wire ~ 3rd Party Press Release
-
2020/05/28
Three-quarters of patients receiving Dupixent achieved at least a 75% improvement in overall disease, with an average improvement of approximately 80%.
Sanofi Seeking Billions from Mylan in EpiPen Antitrust Suit
Dave Bloom
-
2019/08/13
Sordid details of anticompetitive behavior alleged in court filing.
FDA Approves Dupixent® (dupilumab) for Moderate-to-severe Atopic Dermatitis in Adolescents
News Wire ~ 3rd Party Press Release
-
2019/03/12
Therapy targets the IL-4/IL-13 pathway, a key driver of the allergic or type 2 inflammation that underlies atopic dermatitis.
Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...
News Wire ~ 3rd Party Press Release
-
2018/10/15
Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101.
Phase II Trials of AR101 with Dupilumab for Peanut Allergy to...
Dave Bloom
-
2018/09/27
Study scheduled to commence next week.
Study: Dupilumab Showed Positive Phase 3 Results in Adolescents with Inadequately...
News Wire ~ 3rd Party Press Release
-
2018/05/17
"[dupilumab] blocks the IL-4/IL-13 pathway, which is emerging as a central driver of Type 2 allergic inflammation."
Aimmune Issues Update on AR101 Peanut Oral Immunotherapy Candidate
Dave Bloom
-
2018/01/08
The company announces their timeline for continued progress toward an FDA approved standardized therapy.
Aimmune, Regeneron and Sanofi Collaborate on Combination Peanut Therapy
Dave Bloom
-
2017/10/19
More exciting news as pharma companies work to extend the effectiveness of their therapies in combination.
Auvi-Q Takes Center Stage at School Nurse Conference
Dave Bloom
-
2017/07/05
One example of the changing market dynamics for epinephrine auto-injectors in light of recent developments.
Mylan's Chairman Was Paid $97.6 Million
Dave Bloom
-
2017/05/03
Despite 2016 being a year when everything seemed to implode for the marketer of EpiPen.
1
2
3
Page 1 of 3